Lentinan
 | |
| IUPAC ime | |
|---|---|
β-D-glukopiranozil-(1→6)-[β-D-glukopiranozil-(1→3)-[β-D-glukopiranozil-(1→6)]-β-D-glukopiranozil-(1→3)-β-D-glukopiranozil-(1→3)β-D-glukopiranozil-(1→3)]-β-D-glukopiranoza | |
| Klinički podaci | |
| Drugs.com | Internacionalno ime leka |
| Identifikatori | |
| CAS broj | 37339-90-5  |
| ATC kod | L03AX01 (WHO) |
| PubChem | CID 37723 |
| KEGG | D01695 |
| Sinonimi | (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol |
| Hemijski podaci | |
| Formula | C42H72O36 |
| Molarna masa | 1152.99948 g/mol |
Lentinan je beta-glukan sa glikozidnim β-1,3:β-1,6 vezama.[1] On je antitumorni polisaharid iz šitake (Lentinula edodes) pečurke.[1] Lentinan je polisaharid sa molekulskom težinom od oko 500.000 Da. Japanska farmaceutska kompanija Ajinomoto je razvila lek Lentinan, koji se intravenozno dozira kao agens protiv kancera.[2]
Lentinan je jedan od lekova protiv kancera[3] za koji je pokazano da utiče na odbrambeni imunski sistem domaćina.[4]
Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.[5][6][7][8][9][10][11][12]
Vidi još
[уреди | уреди извор]Reference
[уреди | уреди извор]- ^ а б Cancer Guide Архивирано на сајту Wayback Machine (31. децембар 2012) Includes many abstracts
- ^ „Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments”.
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^ Yang P; Liang M; Zhang Y; Shen B. (2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”. Adv Ther. 25 (8): 787—94. PMID 18670743. doi:10.1007/s12325-008-0079-x.
- ^ Nimura H, Mitsumori N, Takahashi N (2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”. Gan to Kagaku Ryoho. 33 (1): 106—9. PMID 16897983.
- ^ Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061.
- ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”. Anticancer Res. 29 (7): 2739—45. PMID 19596954.
- ^ Hazama S; Watanabe S; Ohashi M; et al. (2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”. Anticancer Res. 29 (7): 2611—7. PMID 19596936.
- ^ Kataoka H; Shimura T; Mizoshita T; et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”. Hepatogastroenterology. 56 (90): 547—50. PMID 19579640.
- ^ Isoda N; Eguchi Y; Nukaya H; et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”. Hepatogastroenterology. 56 (90): 437—41. PMID 19579616.
- ^ Shimizu K; Watanabe S; Watanabe S; et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”. Hepatogastroenterology. 56 (89): 240—4. PMID 19453066.
Literatura
[уреди | уреди извор]- Chihara, G. et al. ”Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom)”, Cancer Research (1970),30(11):2776-2781.
- Ina, K. et al. “Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy”, World Journal of Clinical Oncology (2011),2(10):339-343.
Spoljašnje veze
[уреди | уреди извор]
- Lentinan effects (antitumor and others)